Free shipping on orders over £45

The FSA’s First CBD Approvals Explained: What Changes for UK Buyers

In September 2026 the Food Standards Agency recommended the first three CBD products for authorisation as novel foods, and asked its board to agree that the recommendations go to ministers.

Field of tall green hemp plants under a cloudy sky

Last updated: November 2026

In September 2026 the Food Standards Agency recommended the first three CBD products for authorisation as novel foods, and asked its board to agree that the recommendations go to ministers. All three are at least 98% pure CBD, capped at 10mg a day, and must carry warnings for under-18s, pregnancy and people on medication. Ministers in England and Wales now make the final decision.

It is the biggest step in UK CBD regulation since 2019, and it comes with a twist: a new UK and EU food agreement could change who approves CBD altogether. Here is what was decided, what it means for the CBD you buy, and what we think.

What did the FSA decide?

Since 2019, CBD sold as food or a food supplement in the UK has counted as a “novel food”. That means each product needs formal approval before it is fully authorised. For seven years, no CBD product had got all the way through. In September 2026 that changed.

The FSA has recommended three applications to ministers (its board was asked to agree this on 16 September 2026; we will update this page when the minutes are published):

Application Type of CBD Purity Maximum daily amount
RP7 Synthetic CBD 98% or more 10mg
RP350 CBD isolate 98% or more 10mg
RP427 CBD isolate from hemp 98% or more 10mg

Products made under these approvals will have to carry warnings that they are not suitable for under-18s, people who are pregnant, breastfeeding or trying to conceive, or people who take medication or have a weakened immune system. They must also meet strict limits on THC and other controlled cannabinoids.

Around 3,000 of the 8,147 products on the FSA’s public list are linked to these three applications. The recommendation now goes to ministers in England and Wales, who make the final decision. Scotland has its own process through Food Standards Scotland, and Northern Ireland follows a separate route.

Our pick

CBD Oil Broad Spectrum

Broad Spectrum CBD Oil is just broad spectrum CBD and coconut MCT oil, in 500mg, 1,000mg or 2,000mg. 10mg is 0.2ml, 0.1ml or 0.05ml (half a pipette is 0.35ml).

Add Broad Spectrum CBD Oil 500mg to bag or choose another strength

Broad spectrum with 0% THC, every batch third-party lab tested, on the FSA public list, made in the UK from US-grown hemp. For adults only. We don’t recommend our products during pregnancy or breastfeeding. Free UK delivery over £45.

Subscribe from £18.74One-off from £24.99

View product

Which CBD brands are on the FSA public list?

The public list covers products, not brands, so search it by name. Open the FSA’s searchable register (linked from the gov.uk public list page), type the brand or product, and read each result’s status and application number. In November 2026 it held 12,115 entries (last updated 13 April 2026).

  • Validated: the application has all the information the FSA needs for its safety assessment. The product can stay on sale while it is assessed. It is not an authorisation.
  • Awaiting evidence: not yet validated but progressing to an agreed deadline. The product can stay on sale for now.
  • Removed: the linked application has dropped out, and the product should be withdrawn from sale.

Evopure’s CBD oils and capsules are listed as Validated under RP438 (Broad Spectrum, Flow, Sleep and Relief oils and Broad Spectrum CBD Capsules) and RP821 and RP47 (Evolabs). Other examples from the register:

Brand Application Status
Evopure RP438, RP821, RP47 Validated
Pureis RP7 (one of the three recommended) Validated
Cannaray RP350 (one of the three recommended) Validated
British Cannabis RP252, RP256 Validated
Naturecan RP105 and others Validated

What it means for Evopure products

Where our products stand: Evopure’s CBD products are on the FSA’s public list, linked to validated applications RP438, RP821 and RP47. That means they can be legally sold while those applications go through the FSA’s full safety assessment. They are not among the first three recommended for authorisation, which cover about 3,000 of the 8,147 products on the list.

In other words, we are in the same position as most of the UK market. “Validated” means an application passed the FSA’s initial checks. After that comes the full safety assessment, a safety opinion, a board recommendation and, finally, a decision by ministers. We will update this page as our applications move forward.

Every batch of our CBD is third-party tested, and you can request the report for any batch on our lab testing page.

Why 10mg, and the EU’s 2mg view

The FSA originally advised healthy adults to take no more than 70mg of CBD a day. In October 2023 it cut that to 10mg a day, which it says is roughly 4 to 5 drops of a 5% CBD oil. The new approvals use the same 10mg ceiling.

Europe has gone further. In February 2026 the European Food Safety Authority set a provisional safe level of 0.0275mg per kilogram of body weight a day for pure CBD. For a 70kg adult, that is about 2mg a day. Both regulators describe their figures as precautionary, because long-term research is still limited.

The FSA’s 10mg a day figure is precautionary advice rather than a legal limit, set while longer-term safety research continues. At Evopure we think it is a very cautious figure, and many adults use more. If you go above it, increase slowly, and check with your GP or pharmacist first if you take any medication. Our guide to the CBD daily limit in the UK goes into more detail.

“After seven years, UK customers deserve a properly regulated CBD market, so we welcome the first approvals. But 10mg is a precautionary figure, set with a large safety margin while research continues, and many adults use more. Our advice is simple: buy from a brand on the FSA public list with published lab reports, start low, and speak to your pharmacist if you take medication.”

Martin Travis, co-founder, Evopure

The twist: the UK and EU food agreement

The UK and the EU are negotiating a food and farming agreement, known as the SPS agreement, which would line up UK food rules with EU ones. The FSA’s own board papers say that once it comes into force, approvals granted in Great Britain would stop applying, and businesses would need an EU authorisation instead. The chair of the FSA has said the long-term future of the UK CBD sector is likely to lie with EU authorisations.

What that means in practice, and when, is not yet clear, and the EU’s own CBD approvals are still working through its system. For now, the UK public list is still what counts, and nothing changes for customers overnight.

What to look for when you buy CBD

This decision is a good moment to check what you are buying. Five quick checks:

  1. Is it on the FSA public list? A reputable brand will tell you, or you can search the list yourself on the FSA website.
  2. Are there lab reports? Look for an up-to-date certificate of analysis for each batch. Our guide to reading CBD lab reports shows you what to check.
  3. Is the THC level clear? Broad spectrum and isolate products should show no detectable THC.
  4. Can you work out the dose? The label should tell you how much CBD is in each drop or capsule.
  5. Do you take medication? CBD can interact with some medicines. Read our guide to how CBD interacts with medicines and speak to your pharmacist.

For a fuller checklist, see best CBD oil UK: how to choose a quality brand, and if you are new to the terms, what full spectrum CBD means.

Timeline: how we got here

When What happened
January 2019 CBD extracts are classed as a novel food, so products need approval
February 2020 The FSA sets a deadline of 31 March 2021 for businesses to submit valid applications, and advises no more than 70mg a day
March 2022 The FSA publishes its public list of CBD products linked to applications
October 2023 The FSA lowers its advice to 10mg a day for healthy adults
July 2025 The FSA sets a safe upper limit for THC in CBD products of 0.07mg a day for a 70kg adult
February 2026 The European Food Safety Authority sets a provisional safe level of about 2mg a day
September 2026 The FSA asks its board to agree its recommendations on the first three CBD authorisations, to go to ministers
Next Ministers decide; the UK and EU agreement may change who approves CBD

Related guides

Sources 5

  1. Food Standards Agency. CBD novel food applications: recommendations to ministers on first authorisations (September 2026 board meeting).
  2. Food Standards Agency. Cannabidiol (CBD): consumer advice.
  3. Food Standards Agency. CBD products linked to novel food applications (the public list).
  4. European Food Safety Authority (2026). Update of the statement on safety of cannabidiol as a novel food. EFSA Journal.
  5. The Grocer (2026). FSA to recommend first CBD products are authorised for sale.

This article is general information, not legal or medical advice.

Written by

Co-founder, Evopure

Martin co-founded Evopure and writes about sleep, stress and recovery. Our articles are general information, not medical advice.

Questions, answered

No. The September 2026 decision is about approving CBD products, not banning them. CBD products on the FSA's public list can still be sold while their applications are assessed.

The FSA's 10mg a day figure is precautionary advice for healthy adults, not a legal limit. Many adults use more. If you do, increase slowly, and check with your GP or pharmacist first if you take any medication.

It is the FSA's list of CBD food products linked to novel food applications it has accepted for assessment. Products on the list can be sold while the process continues. Being on the list is not an FSA endorsement.

Brands with validated products include Evopure (RP438, RP821, RP47), Pureis (RP7), Cannaray (RP350), British Cannabis and Naturecan. Search the FSA register to check any product.

Our CBD products are on the FSA public list, linked to validated applications RP438, RP821 and RP47, so they can continue to be sold. They are not among the first three applications recommended for authorisation, and we will update this page as they progress.

None is fully authorised yet. The FSA has recommended three applications, RP7, RP350 and RP427, all at least 98% pure CBD with a 10mg daily maximum. Ministers in England and Wales make the final decision.

Not immediately. Nothing changes on shelves until ministers decide, and brands linked to other applications carry on as before while they are assessed.

Shop the article

Mentioned in this article

New here? Join our emails for 20% off your first order.

Here's your 20% off.

WELCOME20
Shop
Evopure
★ 4.7  ·  500,000+ customers  ·  UK made